ISIA Board of Directors and Officers
-
Business Director for Serum
Corning Life Sciences
Mark Koza serves as Business Director for Media & Serum at Corning Life Sciences, where he has spent his two-decade career. He is responsible for strategy and execution of Corning's global serum portfolio, which includes all stages in the supply chain from supply to customer.
Over the years at Corning Life Sciences, Mark has held various roles in commercial and business operations, most recently as Global Business Manager for Serum. He is also a member of the ISIA Traceability team and serves as the ISIA board chair-elect.
Mark received his bachelor’s degree in microbiology from The University of Maine. Outside of work, Mark lives with his wife and two children in the beautiful Seacoast region of New Hampshire.
-
VP of Operations and Communication
Central Biomedia Inc.
Nicole Green has been involved in the animal serum industry for over 20 years and is currently Vice President of Operations and Communication at Central Biomedia, Inc. She has served in many different roles including quality, production, and management. During her tenure she has been responsible for regulatory affairs, quality, business development, and overall company culture. Nicole has been actively involved in the ISIA as leader of the Traceability Team and is now board chair.
Nicole believes in providing safe materials to end users who are producing and researching life-saving products for humans and animals.
Nicole holds a BA in Biology from MidAmerica Nazarene University. She enjoys reading, listening to podcasts, and learning something new every day. She resides in Kansas City, Missouri with her husband and two children.
-
Founder & CEO
Ambioxera Pty Ltd
Mr. Monroy a wealth of experience and expertise in quality management, strategic leadership, and operational excellence to the table. With a dynamic background spanning various sectors including biotechnology, healthcare, and manufacturing, he has consistently demonstrated a commitment to driving organizational success through innovation, collaboration, and thorough attention to detail.
As the Chief Executive Officer and founder of Ambioxera Pty Ltd, Mr. Monroy exemplifies visionary leadership, spearheading the company's strategic direction while fostering a culture of continuous improvement and customer-centricity. His track record of effectively navigating complex regulatory landscapes and ensuring adherence to stringent quality standards underscores his dedication to excellence in every aspect of business operations. He is playing a pivotal role in shaping the company's trajectory by developing and implementing strategic initiatives that drive growth and sustainability.
With a Master's degree in Applied Science with an emphasis in Biotechnology and an MBA with a focus on General Management and more than 10 years of experience in the serum industry, Mr. Monroy possesses a unique blend of technical expertise and business acumen. His bilingual proficiency in Spanish and English further enhances his ability to connect with diverse stakeholders and navigate global business landscapes with ease.
-
Director of Product Management
Cytiva
Jared Deppe is the Director of Product Management - Sera, Research, and OEM Products within Cytiva’s cell culture business (HyClone). He manages commercial and product strategies for HyClone serum and research portfolios with Cytiva.
His 20-year career includes various roles in pricing, finance, and product management. For the last 10 years, Jared has been a leader within Cytiva’s serum portfolio and the serum industry. Jared has also served in multiple functions within the ISIA including as CFO and as an active member of the traceability committee.
Jared holds a Bachelor’s degree from Utah State University in Finance and Economics and a Master’s degree in Business Administration (MBA) from Weber State University.
He resides in Northern Utah with his wife and three daughters.
-
International Sales Manager
River City Biologicals, River City Brazil, and Animal Technologies, Inc.
Ph.D. in Business Administration, Guilherme Esteves is a Board Member of the International Serum Industry Association (ISIA) and holds positions as International Sales Manager at River City Biologicals, River City Brazil, and Animal Technologies, Inc.
With 15+ years of experience in planning and management of commercial, administrative, and financial areas of small and medium-sized companies, Esteves has been working for 11+ years as an entrepreneur, focusing on new business development.
-
Managing Director, ISIA, Past Board Chair
Life Science Group Ltd.
Jenny has over 30 years’ experience in the cell culture industry, both in the UK and worldwide. Jenny is the past owner of Seralab Ltd. and the current owner of Life Science Group Ltd. (LSG). LSG is an independent manufacturing company based in the UK offering contract manufacturing of various human and animal sera, media and buffers for research, cell therapy and other disciplines. LSG also offers the contract manufacture of antibodies, monoclonal and polyclonal, together with a large range of associated services.
Jenny is very active in support of European Regulatory Affairs, Traceability and Standardization within the Association. She recently served 3 years as the Chair of the ISIA Board of Directors.
-
Head of Operations
Moregate Biotech
Originally from Ukraine, Vlad graduated from the National University of Life and Environmental Sciences of Ukraine (formerly National Agricultural University) with a degree in veterinary medicine with honors.
After moving to Australia in 2012 he worked as a beef farm manager prior to joining Moregate Biotech in 2017 and has worked though all levels of the business, from Production Manager to General Manager.
He enjoys the daily challenges, loves to contribute and support the company’s growth, and is fascinated by the vastness of animal serum applications on a global scale. Inspired by James Dunster and Elizabeth Meixner, Vlad’s role has grown to manage the operations of Moregate under new owners after the company was acquired by ANZCO foods in 2022.
Vlad lives with his wife and two children in Brisbane, Australia.
-
Sales and Marketing Director
TCS Biosciences
Gareth has worked for TCS Biosciences Ltd (TCS) for over 20 years and has held the position of Sales and Marketing Director since 2006. TCS is a manufacturer and distributor of a wide range of animal and human derived blood and serum products.
We produce Donor Horse Serum from our herds based on our farm in the UK. It is essential that we maintain high quality standards in all aspects of serum production from animal husbandry, through collection to processing and packaging to ensure consistent top-quality products. We recognize that traceability is of prime importance to our customers, and we are renowned for the quality of our documentation trail and our rapid response to specialist customer requirements.
As well as our own manufactured products, we work with carefully selected strategic partners from around the globe importing Bovine Serum products, including Fetal Bovine Serum, for supply to our customers in the UK and Europe.
TCS has been a member of the ISIA for many years and take active roles in some of the sub committees. In 2017 we confirmed our commitment to quality and ethics by becoming ISIA Traceability Certified. This certification covers the manufacture and supply of our own Donor Horse Serum, and the import, handling and logistical pathway of Bovine Serum products sourced from our ISIA Traceability Certified partners.
-
Courtney Burnam is the Chief Financial Officer of ISIA, bringing over 12 years of experience in accounting and finance. She currently serves as Controller for Animal Technologies, a role she has held since December 2022, where she oversees financial operations and supports strategic initiatives.
Courtney is recognized for her strong financial leadership, analytical expertise, and commitment to organizational excellence.
-
Kathryn Pagani-Lee is the Director of Administration and Board Secretary at the International Serum Industry Association (ISIA). Since joining ISIA in 2021, she has played a pivotal role in managing administrative operations, coordinating board activities, overseeing the successful execution of the ISIA Annual Meeting, and fostering strong member relations.
With a deep commitment to ISIA’s mission, Kathryn ensures the seamless operation of the association while supporting initiatives that promote traceability, regulatory compliance, and ethical standards within the global serum industry. Her expertise in organizational management and stakeholder engagement has been instrumental in strengthening ISIA’s industry presence and enhancing collaboration among its members.
Based in Ontario, California, Kathryn continues to drive ISIA’s efforts to uphold the highest standards in the serum and biological products sector, ensuring its members receive exceptional support and guidance.